References
- Manning G, Whyte DB, Martinez R, et al. The protein kinase complement of the human genome. Science 2002;298:1912–34
- Cohen P. The role of protein phosphorylation in human health and disease. Eur J Biochem 2001;268:5001–10
- Khadjavi A, Barbero G, Destefanis P, et al. Evidence of abnormal tyrosine phosphorylated proteins in the urine of patients with bladder cancer: the road toward a new diagnostic tool? J Urol 2011;185:1922–9
- Cicenas J, Urban P, Küng W, et al. Phosphorylation of tyrosine 1248-ERBB2 measured by chemiluminescence-linked immunoassay is an independent predictor of poor prognosis in primary breast cancer patients. Eur J Cancer (Oxford, England: 1990) 2006;42:636–45
- Gavrin LK, Saiah E. Approaches to discover non-ATP site kinase inhibitors. Med Chem Comm 2013;4:41–51
- Zhang J, Yang PL, Gray NS. Targeting cancer with small molecule kinase inhibitors. Nature Rev Cancer 2009;9:28–39
- Valiathan RR, Marco M, Leitinger B, et al. Discoidin domain receptor tyrosine kinases: new players in cancer progression. Cancer Metast Rev 2012;31:295–321
- Yamanaka R, Arao T, Yajima N, et al. Identification of expressed genes characterizing long-term survival in malignant glioma patients. Oncogene 2006;25:5994–6002
- Johansson FK, Goransson H, Westermark B. Expression analysis of genes involved in brain tumor progression driven by retroviral insertional mutagenesis in mice. Oncogene 2005;24:3896–905
- Heinzelmann-Schwarz VA, Gardiner-Garden M, Henshall SM, et al. Overexpression of the cell adhesion molecules DDR1, Claudin 3, and Ep-CAM in metaplastic ovarian epithelium and ovarian cancer. Clin Cancer Res 2004;10:4427–36
- Weiner HL, Huang H, Zagzag D, et al. Consistent and selective expression of the discoidin domain receptor-1 tyrosine kinase in human brain tumors. Neurosurgery 2000;47:1400–9
- Ford CE, Lau SK, Zhu CQ, et al. Expression and mutation analysis of the discoidin domain receptors 1 and 2 in non-small cell lung carcinoma. Brit J Cancer 2007;96:808–14
- Elkamhawy A, Lee J, Park B-G, et al. Novel quinazoline-urea analogues as modulators for Aβ-induced mitochondrial dysfunction: design, synthesis, and molecular docking study. Eur J Med Chem 2014;84:466–75
- http://www.dtp.nci.nih.gov/
- http://www.reactionbiology.com/
- Monks A, Scudiero D, Skehan P, et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 1991;83:757–66
- Boyd MR, Paull KD. Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen. Drug Devel Res 1995;34:91–109
- Richters A, Nguyen HD, Phan T, et al. Identification of Type II and III DDR2 Inhibitors. J Med Chem 2014;57:4252–62
- http://www.schrodinger.com/Maestro
- Canning P, Tan L, Chu K, et al. Structural mechanisms determining inhibition of the collagen receptor DDR1 by selective and multi-targeted type II kinase inhibitors. J Molec Biol 2014;426:2457–70
- Kim H-G, Tan L, Weisberg EL, et al. Discovery of a potent and selective DDR1 receptor tyrosine kinase inhibitor. ACS Chem Biol 2013;8:2145–50